Cangene halts Phase II hepatitis C trial

Cangene (TSE:CNJ) announced after market close that it stopped a pilot Phase II trial of its anti-hepatitis C virus (HCV) hyperimmune globulin treatment in liver transplant patients after a DSMB revie...